ArticleOncotarget2017

Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma.

Cinzia Pellegrini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.